A Proprietary Methodology to Map, Evaluate and Monitor the Global Biotech Landscape

Biotech investment requires navigating thousands of companies, clinical programs, and biological hypotheses simultaneously. Most funds do this manually — which means slowly, selectively, and reactively.

Dreavent is building a different model.

The Dreavent Engine is a proprietary AI-powered intelligence system designed to give Dreavent's investment team and portfolio companies a structured, continuous view of the global biotech landscape — mapping opportunities, assessing biomarker and endpoint landscapes, evaluating biological risk, and monitoring the market in real time.

01
Opportunity Mapping

The Engine maps the biotech universe against Dreavent's investment thesis using a structured biological framework: indication, pathway, target, modality, mechanism of action, and biomarkers. For each therapeutic area, it identifies where competition is concentrated, where meaningful scientific differentiation exists, and where pharmaceutical demand is present but underserved.

The Engine also tracks investment activity from leading pharmaceutical companies and top-tier biotech funds, monitoring which targets, technologies, and therapeutic approaches are attracting institutional capital, how different scientific approaches compare, and where strategic investors are placing their bets.

This combined view of the scientific and investment landscape allows Dreavent to prioritize opportunities with both biological merit and confirmed market validation and deprioritize saturated or commoditized spaces.

02
Biomarker Intelligence

The FDA and EMA continuously validate new biomarkers and clinical endpoints. The Engine monitors this regulatory landscape in real time, complemented by continuous scanning of scientific publications and active clinical programs where emerging biomarkers appear before reaching regulatory validation.

For each tracked program, the Engine provides the Translational Unit with two structured outputs:

  • A list of potential biomarkers and endpoints drawn from comparable clinical programs and validated regulatory frameworks

  • A list of potential indication repositioning opportunities where the same target or mechanism of action may address confirmed pharmaceutical demand in a more favorable environment

Portfolio companies also benefit directly from this intelligence to optimize their clinical development strategy.

03
Probability of Success Assessment

Before any investment decision, the Engine applies a structured pre-IND de-risking framework to assess whether the therapeutic hypothesis is sufficiently validated to justify capital deployment. The framework evaluates four layers of risk:

  • Indication risk: the biological understanding of the disease and strength of unmet medical need

  • Biological risk: the degree of target validation and pathway dominance

  • Mechanism risk: whether the modality is appropriate and sufficiently differentiated

  • Measurement risk: the availability of translational biomarkers and clarity of early clinical readouts

The output is a structured risk profile for each candidate program: a systematic input for the Investment Committee, not a replacement for its judgment.

The first MVP of the Dreavent Engine is expected to be operational within the first months following fund closing.